Drug updated on 9/4/2024
| Dosage Form | Injection (subcutaneous; 0.4 mg, 0.56 mg, 1.2 mg) |
| Drug Class | C type natriuretic peptide analogs |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated to increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses.
Latest News
Summary
- Voxzogo (vosoritide) is indicated to increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses.
- This summary is based on the review of one systematic review(s)/meta-analysis(es). [1]
- Vosoritide and Growth Hormone (GH): Both vosoritide and GH are effective in increasing height or growth velocity in individuals with achondroplasia. However, the long-term effects of GH are unclear, and the data on vosoritide are limited to a few studies.
- Limb Lengthening: Limb lengthening is effective for height increase in achondroplasia patients but is associated with complications, which may make it less favorable compared to vosoritide and GH.
- Population Differences: The provided summary does not identify any differences in effectiveness among different population types or subgroups with achondroplasia.
- There is no detailed safety information available for vosoritide and GH in the reviewed studies.
- There is no information available on population types or subgroups in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Voxzogo (vosoritide) Prescribing Information. | 2023 | BioMarin Pharmaceutical Inc., Novato, CA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Burden and treatment of achondroplasia: a systematic literature review. | 2023 | Advances in Therapy |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Emerging therapies for the treatment of rare pediatric bone disorders. | 2022 | Frontiers in Pediatrics |